Context: Ectopic GHRH secretion is a rare cause of acromegaly, and case reports are mainly isolated.
We reviewed 53 cases of acromegaly induced by an ectopic GHRH secretion that have been reported in the international literature since this date , mainly as isolated case reports but with one series of three patients reported by Biermasz et al. (20) . The reported follow-up periods are often short, mainly less than 2 yr, meaning that little information is held regarding long-term prognosis.
Plasma GHRH assay has proven a sensitive method to confirm an ectopic source of GHRH secretion (2, 59) . In France, such assays have been performed by a single laboratory since 1983. This gave us the unique opportunity to perform a nationwide survey and identify and retrospectively analyze a large series of 21 cases of acromegaly caused by an ectopic secretion of GHRH and assess its etiology, clinical, biological, and radiological features, treatment, and prognosis as well as evaluate the usefulness of determining GHRH levels during the follow-up.
Patients and Methods

Patients
Although plasma GHRH higher than 300 ng/liter is usually reported in literature, three cases of acromegaly due to ectopic secretion of GHRH have been reported with plasma GHRH between 100 and 300 ng/liter (14, 16, 23) . To avoid overlooking cases with mildly elevated GHRH, we identified all patients between 1983 and 2008 with plasma GHRH exceeding 100 ng/liter from the registry of the East Biological Center of the University Hospital of Lyon performing GHRH assays for all centers in France.
From the 30 identified patients, we included those with an acromegaly confirmed by the following diagnostic criteria: a high IGF-I compared with age-matched control and/or a lack of GH suppression, after an oral glucose overload. GH suppression was defined as GH under 1 g/liter between 1983 and 2004 or under 0.3 g/liter for assays performed after 2004 (60) . Nine patients were excluded based on the absence of evidence of acromegaly (n ϭ 3), lack of medical records (n ϭ 3), absence of follow-up (n ϭ 2), or death before exploration (n ϭ 1). Finally, we selected 21 acromegalic patients from 12 different medical centers. Patient 13 had already been described by Caron et al. (61) .
Patients were considered in remission when IGF-I concentration had been normalized and imaging showed no evidence of tumor recurrence.
Biological assessment
Plasma GHRH was measured using a double-antibody RIA developed in our laboratory (62) . Circulating GHRH concentration was below the detection limit (Ͻ30 ng/liter) in normal subjects.
Reference values for GH and IGF-I assays were different between centers, so we chose to express IGF-I values relative to the upper normal limit (UNL) established by each center.
Histology
The endocrine nature was confirmed in 16 of the 20 identified tumors by the histological analysis either of the removed tumor or of a biopsy. Tumors were classified according to the World Health Organization classification of 2000 (pancreatic tumors) (63) and 2004 (bronchial carcinoid) (64) .
For the four remaining tumors, both elevated plasma GHRH and abnormal uptake on somatostatin receptor scintigraphy (SRS) were considered as sufficient to confirm the endocrine nature of the tumor.
Statistical analysis
We used the Statview software for statistical analysis. We used the nonparametric Spearman's correlation and MannWhitney U test. Results were considered as statistically significant when P Ͻ 0.05.
Results
Characteristics of acromegalic patients
Patient features are summarized in Table 1 . The median age at diagnosis was 36 (14 -77) yr. Male to female sex ratio was 1:2.
Clinical acromegaly of variable intensity revealed the disease in 20 of the 21 patients. IGF-I values ranged from 1.1-to 4.2-fold the UNL of age-matched controls (median ϭ 2.6-fold). Basal GH values ranged from 2.5-256 g/liter (median 17.25 g/liter), and GH was not suppressed during the oral glucose tolerance test (OGTT) (n ϭ 10).
Patient 11 was diagnosed during systematic follow-up because of a family history of multiple endocrine neoplasia type 1 (MEN1) with a GHRH-secreting pancreatic tumor in his mother (patient 1). Plasma GHRH slightly exceeded normal levels at 21 yr (35-80 ng/liter) and became pathological 16 yr later when a pancreatic tumor was diag-nosed. IGF-I was only slightly elevated, and GH continued to be suppressed during OGTT.
Pituitary imaging was available for 20 patients: computed tomography (CT) in two historic cases and magnetic resonance imaging (MRI) in the 18 others. It was interpreted as normal in five patients, as showing a pituitary enlargement without evidence of an adenoma in eight (Fig. 1) , and a microcystic lesion in two. Imaging was suggestive of an adenoma in five patients (Table 1) .
A MEN1 germline mutation was identified in the five patients with pituitary adenoma. All had elevated plasma prolactin levels. Two of them have been medically treated with dopaminergic agonist. The three others underwent transsphenoidal pituitary surgery (patients 3, 6, and 7). None of them was cured by the pituitary surgery. The histological analysis showed hyperplasia of somatotroph cells in each case, associated in two cases with a prolactinoma (patients 6 and 7). As previously described, immunohistochemical analysis showed a predominant prolactin (PRL) staining in the adenomatous area associated with a faint GH staining in patient 6 (65) .
Finally, GHRH determination was performed due to the discordance between features of acromegaly and a normal MRI in eight patients, persistence of acromegaly after pituitary surgery in four, and a personal or familial history of endocrine tumor in nine.
Endocrine tumors responsible for the ectopic GHRH secretion
The tumors responsible for the ectopic secretion of GHRH were identified in 20 patients (Table 1) . They were all neuroendocrine tumors.
Twelve patients had a pancreatic tumor; five were single pancreatic tumors with a median diameter of 70 mm (40 -80 mm), and the remaining seven were multiple pancreatic tumors, the largest tumor measuring between 10 and 80 mm in diameter. Two were well-differentiated neuroendocrine tumors; seven were well-differentiated neuroendocrine carcinomas.
A MEN1 gene mutation was identified in eight of the 10 patients with a pancreatic tumor for whom sequencing had been performed. In one patient (case 12) with a past history of bronchial tumor, a pancreatic tumor was discovered during follow-up. Although the exact source of GHRH secretion has not been definitively identified, acromegaly was concomitant with pancreatic tumor occurrence and a long-lasting remission of the bronchial tumor. We considered it reasonable to assume that the offending tumor was pancreatic.
Seven patients had bronchial carcinoid tumors with a median diameter of 45 mm (range 12-80 mm). Five were typical, and one was atypical (case 18). Two patients underwent surgical removal of the bronchial carcinoid a few years before the diagnosis of acromegaly, and the GHRH secretion was related to secondary bone and hepatic metastasis (patients 15 and 18).
GHRH immunostaining was positive on the four tumors tested (patients 1, 3, 13, and 14). Six of the pancreatic tumors and one of the bronchial carcinoid tumors demonstrated a multihormonal production on immunohistochemistry analysis ( Table 1 ).
The responsible tumor was an appendicular well-differentiated endocrine carcinoma for one patient (case 20). The offending tumor remained unknown for another (case 21) despite extensive imaging during 4 yr of follow-up.
Ten patients (47.6%) had distant metastases at the time of the diagnosis of acromegaly; pancreatic tumors were metastatic in 66.6% of cases (n ϭ 8 of 12) and bronchial tumors in 28.6% (n ϭ 2 of 7). Pancreatic tumors mainly metastasized to the liver and bronchial ones to the liver and bones.
Imaging for localization of the endocrine tumor
Imaging used for diagnosis varied according to center and technical progress. Thoracic and/or abdominal CT scan was systematically performed and identified the primary tumor and/or metastases in 20 cases. CT scan showed the pancreatic tumor in nine of the 12 patients. For two patients, it showed isolated liver lesions, and the pancreatic tumor was identified only by the SRS and endoscopic ultrasound. CT scan revealed the bronchial tumor in five patients and the liver metastasis in patients 15 and 18 whose tumor had been previously surgically removed.
SRS using radiolabeled octreotide, performed for 16 patients, showed the primary tumor and/or secondary lesions in 81% of patients. Ultrasound endoscopy identified a pancreatic tumor in all six patients explored.
For patient 21, neither the thoracic and abdominal CT nor the SRS and [ 
Management and outcome
After a median follow-up of 5 yr (range 1-18 yr), three patients died (patients 1, 7, and 19) ( Table 2) .
Pancreatic tumors
Nonmetastatic patients (n ϭ 4) were operated on, and all of them were in remission. One patient (case 1) died from a myocardial infarction after 24 yr of follow-up.
Three (patients 3, 4, and 6) of the eight patients with metastatic pancreatic tumors underwent pancreatic tumor and liver metastases removal. Subsequent chemotherapy (streptozocin, adriamycin) was administered to patient 3. A hepatic recurrence occurred 4 yr later, and a long-lasting remission (8 yr) was obtained after an iterative surgery followed by internal radiotherapy using DOTA-tyroctreotide. At the time of the study, all three patients were considered in remission after a median follow-up of 7 yr.
The five other patients (cases 5, 7, 8, 9, and 12) presenting with multiple metastases were treated with longacting somatostatin analogs, associated in two patients with chemotherapy, hepatic metastases chemoembolization, and/or external pancreatic radiotherapy and/or everolimus. After a median follow-up of 8 yr, two were stable, two presented progressive tumoral disease, and one had died from tumoral progression.
Bronchial carcinoids
An apparently complete surgical removal of the bronchial primary tumor was performed for four of the five patients without metastases. Only one has been treated with a complementary radiotherapy. All were considered in remission after a median follow-up of 9.5 yr (2-20 yr).
Despite a localized disease, patient 19 did not undergo surgeryduetoherageandthepresenceofseverecardiacfailure.She was treated with long-acting somatostatin analogs and died from respiratory failure 1 yr after the diagnosis.
Two patients had metastases (patients 15 and 18). Both underwent hepatic chemoembolization and received chemotherapy and long-acting somatostatin analogs. Partial liver metastases removal was additionally performed in case 15. At last follow-up, one was progressive (case 18), and the other was stable (case 15).
Appendicular primary tumor
Patient 20 has undergone a colectomy and secondary lymphatic metastasis removal. She was considered in remission after 3 yr follow-up.
Unidentified tumor
Patient 21 has been receiving long-acting somatostatin analogs for 4 yr. Despite yearly controls of CT scan and SRS, the tumoral site of GHRH secretion remains unknown.
Usefulness of plasma GHRH assay in diagnosis and follow-up
Diagnosis
Median GHRH at diagnosis was 548 (range 270 -9779) ng/liter. The median GHRH values were 1173 (range 382-9779) ng/liter in bronchial secreting tumors and 539 (range 270 -2600) ng/liter in pancreatic ones. The difference was not significant (P ϭ 0.10) (Fig. 2A) .
GHRH values showed no significant difference between patients with a metastasized tumor (n ϭ 10) and those with a localized tumor (n ϭ 10) (median 546 vs. 728 ng/liter, P ϭ 0.70) (Fig. 2B) . There was no relation between GHRH value and the primary tumor size in patients with unifocal localized tumor at diagnosis (n ϭ 8; P ϭ 0.54). A weak correlation was found between GHRH and IGF-I levels ( ϭ 0.476; P ϭ 0.044).
After surgery
GHRH assay was performed within the year after surgery in 11 of 13 patients (Table 2 and Fig. 3B) .
GHRH was less than 30 ng/liter in the nine patients who underwent a complete tumor removal. In patient 3, who presented a liver recurrence 4 yr after surgery, an elevation of GHRH (251 ng/liter) was observed before the appearance of the metastasis on conventional imaging.
After liver surgery and complementary internal radiotherapy, GHRH remained undetectable for 8 yr.
GHRH remained detectable in two patients. The GHRH values of 71 ng/liter in patient 20 prompted a second intervention for lymph node resection with a right colectomy, achieving undetectable GHRH that persisted 2 yr later. In the second patient (case 15), GHRH remained elevated (709 ng/liter) after only partial resection of liver metastases.
During follow-up, GHRH remained undetectable in nine of the 10 patients considered in remission after surgery. A plasma GHRH concentration of 53 ng/liter was detected 3 yr after surgery in patient 10 for whom the GHRH level had not been previously measured after surgery, but the imaging was negative and IGF-I normalized.
Follow-up under medical treatment with somatostatin analogs
The eight patients who had not been operated on were treated with somatostatin analogs. At last follow-up, three were progressive, two had stabilized, and two had died. IGF-I secretion was normalized in all of them but secondarily in- creased in patient 18 while the tumor was progressing, before being normalized after additional treatment with pegvisomant. Plasma GHRH did not normalize. A median reduction of 61% (range 35-71%) was observed among eight patients receiving somatostatin analogs as the sole treatment over a limited period (Fig. 3) .
Discussion
Ectopic secretion of GHRH by a carcinoid tumor is very rare, and this nationwide multicentric series of 21 acromegalic patients with ectopic GHRH secretion is to our knowledge the largest to date. Although retrospective, this study gives new insight into pituitary features in MEN1 patients, tumor pathology, and prognosis with a median follow-up of 5 yr. Furthermore, all patients underwent GHRH determination in the same laboratory, thus allowing us to evaluate the relationship between GHRH concentration and tumor location, size, and metastasis and demonstrate its usefulness during follow-up. In most patients, the diagnosis was suspected because of clinical and biological manifestations of acromegaly indistinguishable from those of patients with a GH-secreting adenoma. The intensity of acromegaly was highly variable. The diagnosis of ectopic GHRH secretion was obvious when a history of neuroendocrine tumor was known at the time of diagnosis of acromegaly. Twelve of the 21 A, Adrenal; B, bone; CT, chemotherapy; D, day; DA, dopaminergic agonist; DOTATOC, DOTA-Tyr-octreotide therapy; 5FU, 5 fluorouracyl; H, hepatic; LAR, long-acting release; LASA, mean long-acting somatostatin; M, month; Pe, peritoneal; P, pulmonary; S, splenic; RT, radiotherapy. a Adriamycin plus streptozocin.
b Adriamycin plus 5FU plus streptozocin.
c Adriamycin plus streptozocin and 5FU plus streptozocin.
d 5FU plus dacarbazin and streptozocin plus 5FU.
patients, however, had no significant tumoral medical history, and the diagnosis could only be suspected by the lack of evidence of pituitary adenoma at MRI. Importantly, the distinction between hyperplastic and adenomatous lesions is difficult. Indeed, four patients (three of them having MEN1) with suspected macroadenoma underwent tumor resection. For two of them, histology revealed only somatotroph hyperplasia induced by GHRH hypersecretion. This was associated in one case with a mild hyperprolactinemia in whom physiopathology was unclear. A mammosomatotroph phenotype driven by GHRH secretion cannot be excluded. In this retrospective study, there was no centralized reading of exams, and we cannot be sure whether new MRI techniques or delineation would have improved the imaging diagnosis. Nevertheless, this emphasizes the need for careful and rigorous interpretation of the MRI results by an experienced radiologist. The other two MEN1 patients displayed an association of a somatotroph hyperplasia and a microprolactinoma. The pituitary features of one of these cases has already been described (65) . Immunohistochemistry clearly showed distinct immunostaining between the hyperplastic (exclusively GH) and the adenomatous zone revealed by a highly predominant immunostaining with anti-PRL. Thus, in MEN1 patients, the possibility of an association between a neuroendocrine tumor secreting GHRH and a prolactinoma must be considered and may be misleading. When there is any doubt over the presence of an ectopic GHRH secretion, the first step is to determine plasma GHRH levels. This method provides the hormonal evidence for an ectopic source of GHRH secretion because increased GHRH levels have been recorded in all patients with such acromegaly. It has also been shown as highly specific because no patient from a series of 177 consecutive GH-secreting adenomas presented elevated plasma GHRH concentration (59) . Although acromegaly due to an ectopic secretion of GHRH is very rare, 8 -44% of pancreatic and 11-18% of digestive carcinoid tumors express GHRH (66 -69) . The apparent discordance between high incidence of GHRH expression and low incidence of acromegaly may be due to abnormal tissue processing or impaired bioactivity of circulating GHRH (3). This is in accordance with the weak correlation that we found between plasma GHRH values and IGF-I values.
Because a few cases of acromegaly due to an ectopic secretion of GHRH were reported with GHRH between 100 and 300 ng/liter, we first identified for this study all patients with a GHRH value greater than 100 g/liter so as not to exclude patients with a mild elevation of plasma GHRH. After exclusion of patients lost to follow-up or with no evidence of acromegaly, we identified 21 patients with acromegaly. All selected patients had plasma GHRH levels over 250 ng/liter. Only one patient with a GHRH value over 250 ng/liter (750) did not have acromegaly; GHRH was interpreted as a false positive in the context of kidney failure during severe sepsis leading to the death of the patient. Thus, using our assay, the threshold of 250 ng/liter appears as a highly specific indicator of an ectopic GHRH secretion in acromegalic patients. This threshold is close to the 300 ng/ liter currently proposed in the literature. The significance of lower values remains largely unknown. Eleven patients were found to have GHRH between 30 and 100 ng/liter between the years 1997 and 2008, but we unfortunately hold no clinical information on them. It would be interesting to know whether such patients with GHRH values between 30 and 250 have a mild physiological secretion of GHRH or a small as yet undiagnosed GHRH-secreting tumor. Except for patient 11, we did not identify any other patient for whom a mild elevation of GHRH was followed by a secondary increase in GHRH levels and the diagnosis of an endocrine GHRH-secreting tumor. A prospective study should be undertaken to address this issue.
As reported in the literature (Table 3) , primary tumors are pancreatic, bronchial, and digestive neuroendocrine tumors. In this series, and in contrast with the literature, pancreatic tumors were more frequent than bronchial carcinoids (57 and 33%, respectively). In patients with a pan- creatic tumor, a mutation of MEN1 gene was present in eight of the 10 patients tested, suggesting that in such patients, MEN1 mutation should be systematically investigated. The localization of the primary tumor responsible for the ectopic secretion of GHRH was mostly easy, and conventional imaging using a CT scanner was able to identify the primary lesion in most cases (70, 71 ). SRS displayed a good level of sensitivity, and its main interest is in the determination of the endocrine nature of the tumor and localization of metastases. Noteworthy is the lack of significant differences inGHRHplasmaconcentrationwithrespecttotumorlocation, volume, or spread, meaning that GHRH determination cannot be used to assess the site or extent of disease. This could be explained by different degrees of differentiation of tumor cells; however, according to the World Health Organization 2000 classification, all tumors were well differentiated. Whether using the new 2010 classification would have changed the relation remains to be determined. This lack of correlation could also be explained by differences in the proportion of GHRH-secreting cells in tumors. Quantification by GHRH immunostaining would have been informative but was available in only four patients. Another hypothesis would be that tumors produce different forms of GHRH, some being not recognized by the antibody used for the GHRH assay. With the reported follow-up period being generally less than 2 yr in most case reports, this retrospective study gives interesting information about the prognosis. Although distant metastases were frequent at the time of diagnosis of acromegaly, especially in association with pancreatic tumors, the overall prognosis remained excellent with a survival rate of 85% after a median follow-up of 5 yr. This is in agreement with the natural history of well-differentiated neuroendocrine tumors. Prognosis of GHRH-secreting tumors is the same as other neuroendocrine tumors (72, 73) . Surgery was able to induce prolonged remission even in metastatic patients when a complete tumor resection was feasible. These patients had undetectable plasma GHRH levels at postoperative control and during follow-up (Ͻ 30 ng/liter), except one for whom GHRH concentration was detected at 53 ng/liter. Whether such detectable levels correspond to an infraradiological persistent disease or a GHRH concentration without pathological significance is unknown. The follow-up of this patient would appear therefore as important to assess the meaning of this detectable GHRH level.
When surgery was not feasible, somatostatin analog treatment was instituted in all patients. Although this consistently led to IGF-I normalization, GHRH levels always remained high (Ͼ250 ng/liter) despite a median reduction of 61%. This observation, in concordance with the literature (31, 37, 38, 42, 45, 46, 57, 74, 75) , probably illustrates a predominant action of somatostatin analogs on the somatotroph pituitary cells with only a minor effect on the tumoral secretion of GHRH. We therefore observed no reduction in tumor size under somatostatin analog treatment. Overall, during follow-up, plasma GHRH gave accurate information with which to assess likelihood of remission or recurrence. Indeed, GHRH levels were undetectable in 10 of the 11 patients in remission and remained elevated in all patients with persistent disease. Moreover, an increase in GHRH levels was the first manifestation of recurrence in two patients that was secondarily evidenced by imaging. Thus, during the follow-up, GHRH changes accurately indicated recurrences and should be considered for use as a monitoring tool. 
